ResearchPUBMEDYesterday
Researchers studied whether matching cancer treatments to a patient's genetic test results helps people with hard-to-treat advanced cancers live longer. They looked at data from over 1,000 Australian patients with different types of advanced solid tumors who received personalized treatment recommendations based on their tumor's genetic makeup. The study used a ranking system to organize genetic matches by how much scientific evidence supported each match, and then tracked how long patients survived.
WHY IT MATTERSIf you have a rare or treatment-resistant cancer, this research suggests that genetic testing of your tumor could help your doctor choose a therapy specifically matched to your cancer's mutations, potentially improving your survival chances.
ResearchRSS4 days ago
A new study from Australia found that children with spinal muscular atrophy (SMA) who take disease-modifying therapies — medicines approved in the last 10 years that slow down the disease — were able to maintain healthy weight and avoid stunted growth. This is important because children with SMA often have trouble eating and gaining weight. The study looked at children with SMA type 1 and type 2, the most severe forms of the disease.
WHY IT MATTERSFor families managing SMA, this research provides evidence that approved treatments may help prevent malnutrition and growth problems that commonly affect children with this condition, potentially improving long-term health outcomes beyond muscle strength alone.
Clinical trialRSS5 days ago
A company called Neurizon Therapeutics has been approved to test a new liquid version of a drug called NUZ-001 in Australia. This drug is being developed to treat ALS, a disease that affects nerve cells and causes muscle weakness. The company is testing this liquid form in healthy volunteers, while a tablet version of the same drug is already being tested in a larger trial in the United States.
WHY IT MATTERSIf the liquid formulation proves safe and effective, it could offer ALS patients an easier-to-take alternative to a tablet, which may improve medication adherence for people with swallowing difficulties—a common symptom of ALS.
PolicyRSSMay 13
Australia and New Zealand have created new guidelines to help doctors identify and treat spinal muscular atrophy (SMA) in newborns as early as possible. These guidelines combine best practices for screening babies at birth, confirming the diagnosis, and starting treatment right away. This is important because early treatment can significantly improve outcomes for children with SMA.
WHY IT MATTERSIf you live in Australia or New Zealand with a newborn or are planning to have children, these new guidelines mean your baby is more likely to be screened for SMA at birth and treated immediately if affected, which can prevent severe muscle weakness.
ResearchRSSMay 11
A study from Australia found that children with spinal muscular atrophy (SMA) who were caught early through newborn screening and received treatment had better ability to do everyday activities and be independent as they grew up. The children did even better when they received care from a team of different specialists both at home and at school. This shows that finding SMA early and getting coordinated care from multiple doctors and therapists makes a real difference in how well children function day-to-day.
WHY IT MATTERSIf you have a newborn or are planning to have children, this study shows that newborn screening for SMA can identify the condition early enough for treatment to significantly improve your child's independence and quality of life.
PipelineRSSApr 22
A company called Amprion is partnering with a university in Australia to make their alpha-synuclein test more available around the world. This test detects abnormal proteins in the brain that can help doctors diagnose Parkinson's disease and related conditions earlier and more accurately.
WHY IT MATTERSPatients with suspected Parkinson's disease or similar conditions may gain access to a diagnostic test that can identify their specific condition earlier, potentially allowing for treatment to start sooner.